BACKGROUND Tranexamic acid (TXA) is an antifibrinolytic drug associated with improved
survival among trauma patients with hemorrhage. Tranexamic acid is considered a primary …

Objective Trauma is the leading cause of childhood death in the United States. Our goal was
to determine the effectiveness of tranexamic acid (TXA) in improving survival in pediatric …

Background Intravenous tranexamic acid (TXA) reduces bleeding deaths after injury and
childbirth. It is most effective when given early. In many countries, pre-hospital care is …

Objective In the UK there are around 5400 deaths annually from injury. Tranexamic acid
(TXA) prevents bleeding and has been shown to reduce trauma mortality. However, only 5 …

Background Tranexamic acid (TXA) decreases mortality in injured patients and should be
administered as soon as possible. Despite international guidelines recommending TXA in …

Background Tranexamic acid (TXA) is an antifibrinolytic drug used to prevent bleeding. It
was introduced as an intervention for post-traumatic haemorrhage across emergency …

Worldwide, traumatic injury is responsible for over 5 million deaths per year, the majority due
to exsanguination and head injury. The antifibrinolytic drug tranexamic acid is the only drug …

Introduction Hemorrhage is responsible for up to 40% of all traumatic deaths. The seminal
CRASH-2 trial demonstrated a reduction in overall mortality following early tranexamic acid …

Methods Secondary analysis of a perpetual cohort study from a UK Level 1 trauma center.
Adult patients who activated the local major hemorrhage protocol and received TXA were …

Objective Tranexamic acid (TXA) has demonstrated a reduction in all-cause mortality in
trauma patients with hemorrhage. Administering TXA in the prehospital setting presents …